Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow produces too many abnormal white blood cells called B-lymphocytes. These cells look “hairy” under a microscope because of thin, hair-like projections that extend from their surface. It accounts for roughly 2% of all leukemias, with an annual incidence of about 0.7 per 100,000 in men and 0.3 per 100,000 in women in the United States. The median age at diagnosis falls between 56 and 67 years, and men are affected about six times more often than women.
Why It’s Called “Hairy”
The name comes entirely from how the cancer cells look under a microscope. Normal B-lymphocytes have a smooth, round surface. In HCL, the malignant cells develop elongated cytoplasmic projections distributed around their entire circumference, giving them a ragged, hairy appearance. These projections aren’t just cosmetic oddities. They reflect deeper changes in the cell’s internal structure driven by a specific genetic mutation.
The Genetic Driver Behind HCL
More than 97% of hairy cell leukemia cases carry a single mutation called BRAF V600E. This mutation flips on a growth-signaling pathway inside the cell that wouldn’t normally be active, which causes the B-lymphocytes to survive longer than they should, take on their distinctive hairy shape, and resist the body’s normal process for clearing out old or damaged cells. The mutation is now considered the causal genetic event of HCL, meaning it’s not just associated with the disease but actually drives it.
This specificity matters for diagnosis. Among all the B-cell cancers that can look similar under a microscope, the BRAF V600E mutation is essentially unique to classic hairy cell leukemia. Testing for it helps doctors distinguish HCL from look-alike conditions like splenic marginal zone lymphoma or the rarer “variant” form of HCL, which requires different treatment.
What Happens Inside the Body
Hairy cells don’t just circulate in the blood. They accumulate in three main locations: the bone marrow, the spleen, and the liver. The cells carry specific surface receptors that act like molecular Velcro, sticking to the lining of blood vessels in these organs. This is why lymph node swelling, common in many other lymphomas, is relatively uncommon in HCL.
The most damaging effect is what happens in the bone marrow. As hairy cells crowd in, they interfere with normal blood cell production. The result is a condition called pancytopenia, a simultaneous drop in red blood cells, white blood cells, and platelets. This single consequence explains most of the symptoms patients experience. In fact, the hairy cells can pack the marrow so tightly that when doctors try to extract a bone marrow sample with a needle, they often get what’s called a “dry tap,” pulling out no liquid marrow at all.
Symptoms and How It’s Found
Many people with HCL are diagnosed after routine blood work reveals unexplained low blood counts. When symptoms do appear, they tend to develop gradually over weeks or months.
- Fatigue and weakness from low red blood cells (anemia)
- Recurrent or unusual infections from low white blood cells, particularly a type called neutrophils
- Easy bruising or bleeding from low platelet counts
- Abdominal fullness or discomfort from an enlarged spleen, which can grow large enough to feel on physical exam
- Unexplained weight loss and pallor
A markedly enlarged spleen is one of the hallmark findings. Some patients also develop an enlarged liver. Less commonly, HCL has been linked to autoimmune disorders, where the immune system attacks the body’s own tissues.
How It’s Diagnosed
Diagnosis typically involves a combination of blood tests, bone marrow biopsy, and a technique called flow cytometry that identifies specific markers on the surface of cells. Hairy cells light up strongly for a combination of three surface markers (CD103, CD11c, and CD25) while being negative for markers seen in other B-cell cancers. This three-marker combination is considered unique to HCL and often serves as the definitive diagnostic criterion.
When the diagnosis is uncertain, or when hairy cells show up in an unusual location, molecular testing for the BRAF V600E mutation can confirm the diagnosis and rule out similar-looking conditions.
First-Line Treatment
HCL responds remarkably well to a class of chemotherapy drugs called purine analogs. Two drugs in this class have been the standard of care for decades. One is given as an intravenous infusion or subcutaneous injection daily for five to seven days. The other is given intravenously every other week for three to six months. Both achieve complete remission in a high percentage of patients, and many people remain in remission for years or even decades after a single course of treatment.
Not everyone needs treatment right away. Because HCL grows slowly, doctors sometimes take a watch-and-wait approach for patients whose blood counts are only mildly affected and who have no symptoms. Treatment is typically started when blood counts drop to levels that cause symptoms or increase infection risk.
When the Disease Comes Back
While most patients respond well to initial treatment, HCL can relapse. For those who relapse after two or more prior therapies, several targeted options now exist that exploit the biology of the disease.
Because nearly all HCL cells carry the BRAF V600E mutation, drugs that specifically block the BRAF protein have shown strong results. In clinical trials of 54 patients with relapsed or refractory HCL, a BRAF-blocking drug achieved a 91% overall response rate. Combining it with an antibody therapy that targets B-cells pushed complete remission rates from 35% to over 87% and made responses far more durable, with 85% of patients still relapse-free at 34 months of follow-up.
Another option for heavily pretreated patients is a targeted toxin therapy that was approved by the FDA in 2018. In 77 patients who had received a median of three previous treatments, it produced a 77% overall response rate with 43% achieving complete remission. Among those who achieved complete remission, 83% maintained their response at roughly two years of follow-up.
Living With HCL
Hairy cell leukemia has one of the best prognoses of any blood cancer. With modern treatment, most patients live a normal or near-normal lifespan. The disease tends to behave more like a chronic condition that flares occasionally than an aggressive cancer requiring continuous treatment. Many patients go years between treatments, and some never need a second course.
The most significant ongoing concern is infection risk. Even during remission, some patients retain mildly suppressed immune function. Paying attention to fevers, avoiding known sick contacts during periods of low blood counts, and staying current on recommended vaccinations are practical steps that make a real difference. Regular blood work to monitor counts is standard follow-up, typically every few months initially and then less frequently as remission stabilizes.